PL2532367T3 - Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu - Google Patents
Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworuInfo
- Publication number
- PL2532367T3 PL2532367T3 PL11739883T PL11739883T PL2532367T3 PL 2532367 T3 PL2532367 T3 PL 2532367T3 PL 11739883 T PL11739883 T PL 11739883T PL 11739883 T PL11739883 T PL 11739883T PL 2532367 T3 PL2532367 T3 PL 2532367T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- prevention
- treatment
- pharmaceutical agent
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010023455 | 2010-02-04 | ||
| PCT/JP2011/052414 WO2011096535A1 (ja) | 2010-02-04 | 2011-02-04 | 癌の治療及び／又は予防のための医薬品 |
| EP11739883.4A EP2532367B1 (en) | 2010-02-04 | 2011-02-04 | Pharmaceutical agent for treatment and/or prevention of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2532367T3 true PL2532367T3 (pl) | 2019-02-28 |
Family
ID=44355529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11739883T PL2532367T3 (pl) | 2010-02-04 | 2011-02-04 | Środek farmaceutyczny do leczenia i/lub zapobiegania nowotworu |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9180187B2 (pl) |
| EP (1) | EP2532367B1 (pl) |
| JP (1) | JP5923984B2 (pl) |
| KR (1) | KR101843807B1 (pl) |
| CN (2) | CN102844048A (pl) |
| AU (1) | AU2011211700B2 (pl) |
| BR (1) | BR112012018943A8 (pl) |
| CA (1) | CA2788720C (pl) |
| DK (1) | DK2532367T3 (pl) |
| ES (1) | ES2691738T3 (pl) |
| HU (1) | HUE040012T2 (pl) |
| MX (1) | MX2012008991A (pl) |
| PL (1) | PL2532367T3 (pl) |
| PT (1) | PT2532367T (pl) |
| RU (1) | RU2624029C2 (pl) |
| WO (1) | WO2011096535A1 (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0911925B8 (pt) | 2008-08-05 | 2024-02-06 | Toray Industries | Método para detectar um câncer |
| PT2322221E (pt) | 2008-08-05 | 2014-09-19 | Toray Industries | Composição farmacêutica para tratamento e prevenção de cancro |
| PL2532364T3 (pl) | 2010-02-04 | 2016-11-30 | Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi | |
| US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
| CA2788716C (en) | 2010-02-04 | 2019-06-18 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| BR112012018943A8 (pt) | 2010-02-04 | 2017-12-19 | Toray Industries | medicamento e método para o tratamento e/ou prevenção de um câncer |
| ES2583627T3 (es) | 2010-02-04 | 2016-09-21 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| KR101805520B1 (ko) | 2010-02-04 | 2017-12-07 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| PT2741085T (pt) | 2011-08-04 | 2017-06-30 | Toray Industries | Método para a deteção de cancro prancreático |
| RU2624049C2 (ru) | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли |
| MX348578B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| ES2634249T3 (es) | 2011-08-04 | 2017-09-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| HUE030137T2 (en) * | 2011-08-04 | 2017-04-28 | Toray Industries | Pharmaceutical preparation for the treatment and / or prevention of cancer |
| WO2013018886A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の治療及び／又は予防用医薬組成物 |
| EP2818483B1 (en) * | 2012-02-21 | 2017-08-02 | Toray Industries, Inc. | Medicinal composition for treating and/or preventing cancer |
| US9273130B2 (en) | 2012-02-21 | 2016-03-01 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| MX360211B (es) * | 2012-02-21 | 2018-10-24 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| CA2864999C (en) * | 2012-02-21 | 2020-06-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| CN104220095B (zh) * | 2012-03-30 | 2016-09-07 | 东丽株式会社 | 肝癌的治疗和/或预防用药物组合物 |
| CA2869123C (en) | 2012-03-30 | 2021-03-16 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer |
| PL2876447T3 (pl) | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| EP2876446B1 (en) | 2012-07-19 | 2018-12-26 | Toray Industries, Inc. | Method for detecting cancer |
| EP3031826B1 (en) | 2013-08-09 | 2018-10-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| EP3533466A4 (en) | 2016-10-28 | 2020-06-10 | Toray Industries, Inc. | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION |
| BR112020019935A2 (pt) * | 2018-03-30 | 2021-01-26 | Toray Industries, Inc. | medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer |
| US20230140155A1 (en) * | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| US20230139178A1 (en) | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| BR112022018166A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
| BR112022018161A2 (pt) * | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer |
| KR20220152318A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| BR112023026992A2 (pt) | 2021-06-23 | 2024-03-12 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer |
| MX2023014498A (es) | 2021-06-23 | 2024-01-25 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| CA3227698A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2023008461A1 (pl) | 2021-07-27 | 2023-02-02 | ||
| CA3227706A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3230737A1 (en) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| US20250367307A1 (en) | 2022-06-30 | 2025-12-04 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| KR20250052364A (ko) | 2022-08-24 | 2025-04-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| AU2023329564A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2024043252A1 (pl) | 2022-08-24 | 2024-02-29 | ||
| KR20250054778A (ko) | 2022-08-30 | 2025-04-23 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| WO2024048541A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| KR20250118852A (ko) | 2022-12-23 | 2025-08-06 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| AU2024242849A1 (en) | 2023-03-28 | 2025-09-25 | Toray Industries, Inc. | Method for detecting cell membrane protein |
| JPWO2024204685A1 (pl) | 2023-03-31 | 2024-10-03 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0782709T3 (da) * | 1994-09-19 | 2010-03-29 | Ricardo J Moro | Detektering af cancer |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| KR20010083111A (ko) | 1998-07-14 | 2001-08-31 | 길리스 스티브 | 전립선암의 치료 및 진단을 위한 조성물 및 방법 |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| AU3316600A (en) | 1999-02-22 | 2000-09-21 | Torben F. Orntoft | Gene expression in bladder tumors |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| HK1045332A1 (zh) | 1999-04-02 | 2002-11-22 | Corixa Corporation | 用於治療和診斷肺癌的化合物及其使用方法 |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP1224285A4 (en) | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| JP2004526401A (ja) | 2000-03-29 | 2004-09-02 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| WO2002078524A2 (en) * | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) * | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) * | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| US20060121029A1 (en) | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
| WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| EP2003196A3 (en) | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| PT1735348E (pt) | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
| WO2005100998A2 (en) * | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| UA94899C2 (ru) | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Фиксированное дозирование антител к her |
| WO2006089212A2 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| NZ560976A (en) | 2005-03-11 | 2011-06-30 | Univ Johns Hopkins | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| WO2007095186A2 (en) * | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| BRPI0911925B8 (pt) | 2008-08-05 | 2024-02-06 | Toray Industries | Método para detectar um câncer |
| BRPI0912462B1 (pt) | 2008-08-05 | 2022-03-22 | Toray Industries, Inc | Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante |
| PT2322221E (pt) * | 2008-08-05 | 2014-09-19 | Toray Industries | Composição farmacêutica para tratamento e prevenção de cancro |
| AU2010285265B2 (en) | 2009-08-19 | 2015-05-21 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in FFPE material |
| US8642292B2 (en) | 2009-09-22 | 2014-02-04 | Probiogen Ag | Process for producing molecules containing specialized glycan structures |
| US8709418B2 (en) * | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
| BR112012018943A8 (pt) | 2010-02-04 | 2017-12-19 | Toray Industries | medicamento e método para o tratamento e/ou prevenção de um câncer |
| PL2532364T3 (pl) | 2010-02-04 | 2016-11-30 | Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi | |
| CA2788716C (en) | 2010-02-04 | 2019-06-18 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| KR101805520B1 (ko) | 2010-02-04 | 2017-12-07 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| ES2583627T3 (es) | 2010-02-04 | 2016-09-21 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| PT2741085T (pt) | 2011-08-04 | 2017-06-30 | Toray Industries | Método para a deteção de cancro prancreático |
| ES2634249T3 (es) | 2011-08-04 | 2017-09-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| WO2013018886A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の治療及び／又は予防用医薬組成物 |
| CA2869123C (en) | 2012-03-30 | 2021-03-16 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer |
| CN104220095B (zh) | 2012-03-30 | 2016-09-07 | 东丽株式会社 | 肝癌的治疗和/或预防用药物组合物 |
-
2011
- 2011-02-04 BR BR112012018943A patent/BR112012018943A8/pt not_active Application Discontinuation
- 2011-02-04 ES ES11739883.4T patent/ES2691738T3/es active Active
- 2011-02-04 AU AU2011211700A patent/AU2011211700B2/en active Active
- 2011-02-04 JP JP2011510197A patent/JP5923984B2/ja active Active
- 2011-02-04 US US13/576,950 patent/US9180187B2/en active Active
- 2011-02-04 MX MX2012008991A patent/MX2012008991A/es active IP Right Grant
- 2011-02-04 RU RU2012137503A patent/RU2624029C2/ru active
- 2011-02-04 WO PCT/JP2011/052414 patent/WO2011096535A1/ja not_active Ceased
- 2011-02-04 CN CN2011800172337A patent/CN102844048A/zh active Pending
- 2011-02-04 PT PT11739883T patent/PT2532367T/pt unknown
- 2011-02-04 CA CA2788720A patent/CA2788720C/en active Active
- 2011-02-04 EP EP11739883.4A patent/EP2532367B1/en active Active
- 2011-02-04 CN CN201910271408.5A patent/CN109925511B/zh active Active
- 2011-02-04 PL PL11739883T patent/PL2532367T3/pl unknown
- 2011-02-04 DK DK11739883.4T patent/DK2532367T3/en active
- 2011-02-04 HU HUE11739883A patent/HUE040012T2/hu unknown
- 2011-02-04 KR KR1020127022763A patent/KR101843807B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE040012T2 (hu) | 2019-02-28 |
| RU2624029C2 (ru) | 2017-06-30 |
| DK2532367T3 (en) | 2018-11-19 |
| EP2532367A4 (en) | 2014-05-28 |
| KR20120139720A (ko) | 2012-12-27 |
| CN109925511A (zh) | 2019-06-25 |
| US9180187B2 (en) | 2015-11-10 |
| KR101843807B1 (ko) | 2018-03-30 |
| CN102844048A (zh) | 2012-12-26 |
| ES2691738T3 (es) | 2018-11-28 |
| BR112012018943A8 (pt) | 2017-12-19 |
| AU2011211700B2 (en) | 2015-06-11 |
| CN109925511B (zh) | 2024-03-19 |
| CA2788720A1 (en) | 2011-08-11 |
| WO2011096535A1 (ja) | 2011-08-11 |
| PT2532367T (pt) | 2018-11-09 |
| RU2012137503A (ru) | 2014-03-10 |
| MX2012008991A (es) | 2012-09-07 |
| AU2011211700A1 (en) | 2012-08-23 |
| JPWO2011096535A1 (ja) | 2013-06-13 |
| JP5923984B2 (ja) | 2016-05-25 |
| CA2788720C (en) | 2019-08-20 |
| EP2532367A1 (en) | 2012-12-12 |
| US20120294860A1 (en) | 2012-11-22 |
| EP2532367B1 (en) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2532367T (pt) | Agente farmacêutico para o tratamento e/ou prevenção do cancro | |
| PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| PL2532743T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka | |
| HUE046788T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
| PL2740489T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki | |
| PL2740793T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi | |
| PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
| HUE036424T2 (hu) | Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére | |
| IL225471B (en) | Preparations for the prevention and treatment of cancer | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| PL2832366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego | |
| PL2532680T3 (pl) | Kompozycja medyczna do leczenia raka i/lub zapobiegania | |
| PT2322221E (pt) | Composição farmacêutica para tratamento e prevenção de cancro | |
| PL2740796T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740794T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów | |
| PT3031826T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro | |
| IL219073A (en) | A drug combination for cancer treatment | |
| GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
| IL251083B (en) | Compounds and preparations for the treatment of cancer | |
| PL2305300T3 (pl) | Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi | |
| IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer | |
| AU2011211693B2 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| HU1000559D0 (en) | Pharmaceutical compositions for the treatment of osteoporosis and cancer | |
| HK1189502A (en) | Compositions and methods for the prevention and treatment of cancer |